Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.58 |
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493706 | 1.00 | CTSK (0.58) | CTSKCTSSATMCTSGCTRB1 | |
| SCHEMBL13636738 | 0.90 | CTSK (0.56) | CTSKCTSSATMCTSGCTRB1 | |
| SCHEMBL7696221 | 0.88 | CTSK (0.59) | CTSKCTSSATMCTSGCTRB1 | |
| SCHEMBL3842588 | 0.88 | CTSK (0.59) | CTSKCTSSATMCTSGCTRB1 | |
| SCHEMBL14338698 | 0.88 | CTSK (0.59) | CTSKCTSSATMCTSGCTRB1 | |
| SCHEMBL10654828 | 0.87 | ATM (0.46) | CTSKCTSSATMCTSGCTRB1 | |
| SCHEMBL18653949 | 0.86 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL4727222 | 0.86 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL5760296 | 0.86 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL10657769 | 0.86 | ATM (0.46) | CTSKCTSSATMCTSGCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622996-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | King's College London (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2024110757-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | KING'S COLLEGE LONDON (GB) | 2024-05-30 | — | — | WO | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| US-20220195017-A1 | PATHOGEN BINDING METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-06-23 | — | — | US | disclosed |
| US-11021709-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200362350-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-19 | — | — | US | disclosed |
| US-10704049-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200031900-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-10273283-B2 | Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2013-07-04 | — | — | US | disclosed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130064895-A1 | Amphiphilic Peptides and Peptide Particles | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013028843-A1 | PEPTIDE NANOPARTICLES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012177986-A2 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES (IN) | 2012-12-27 | — | — | WO | disclosed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| WO-2004089362-A1 | 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | CTSK 2830/4885CTSS 3462/4885ATM 3383/4885 |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | CTSK 516/4885CTSS 1270/4885ATM 1487/4885 |
| US-10273283-B2 | Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof | ITGA2B, ITGB1, ITGA1 | CTSK 2830/4885CTSS 3462/4885ATM 3383/4885 |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | GHSR, GHRHR, GIPR | CTSK 3353/4885CTSS 1857/4885ATM 2944/4885 |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | CTSK 2830/4885CTSS 3462/4885ATM 3383/4885 |
| US-20200031900-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | CTSK 2830/4885CTSS 3462/4885ATM 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.